Godoy-Ortiz A, et al. - This study was planned to retrospectively assess the efficacy and safety of bevacizumab as the first-line treatment in patients from usual clinical practice with recurrent/persistent or advanced cervical cancer. Despite having certain limitations, this study seemed to provide useful information and encouraging evidence that the routine use of bevacizumab as part of first-line treatment of patients with advanced cervical cancer could be associated with outcomes comparable with those obtained in GOG240 study.